<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/356a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/356a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/356a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_356a"><akn:num>356a</akn:num><akn:heading>Manufacturing changes</akn:heading><akn:content><akn:p>§ 356a. Manufacturing changes(a) In generalWith respect to a drug for which there is in effect an approved application under section 355 or 360b of this title or a license under section 262 of title 42, a change from the manufacturing process approved pursuant to such application or license may be made, and the drug as made with the change may be distributed, if—(1) the holder of the approved application or license (referred to in this section as a “holder”) has validated the effects of the change in accordance with subsection (b); and

(2)(A) in the case of a major manufacturing change, the holder has complied with the requirements of subsection (c); or

(B) in the case of a change that is not a major manufacturing change, the holder complies with the applicable requirements of subsection (d).



(b) Validation of effects of changesFor purposes of subsection (a)(1), a drug made with a manufacturing change (whether a major manufacturing change or otherwise) may be distributed only if, before distribution of the drug as so made, the holder involved validates the effects of the change on the identity, strength, quality, purity, and potency of the drug as the identity, strength, quality, purity, and potency may relate to the safety or effectiveness of the drug.


(c) Major manufacturing changes(1) Requirement of supplemental applicationFor purposes of subsection (a)(2)(A), a drug made with a major manufacturing change may be distributed only if, before the distribution of the drug as so made, the holder involved submits to the Secretary a supplemental application for such change and the Secretary approves the application. The application shall contain such information as the Secretary determines to be appropriate, and shall include the information developed under subsection (b) by the holder in validating the effects of the change.


(2) Changes qualifying as major changesFor purposes of subsection (a)(2)(A), a major manufacturing change is a manufacturing change that </akn:p></akn:content><akn:subsection eId="subsec_356a_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general With respect to a drug for which there is in effect an approved application under section 355 or 360b of this title or a license under section 262 of title 42, a change from the manufacturing process approved pursuant to such application or license may be made, and the drug as made with the change may be distributed, if—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356a_b"><akn:num>(b)</akn:num><akn:heading>Validation of effects of changes</akn:heading><akn:content><akn:p>(b) Validation of effects of changes For purposes of subsection (a)(1), a drug made with a manufacturing change (whether a major manufacturing change or otherwise) may be distributed only if, before distribution of the drug as so made, the holder involved validates the effects of the change on the identity, strength, quality, purity, and potency of the drug as the identity, strength, quality, purity, and potency may relate to the safety or effectiveness of the drug.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356a_c"><akn:num>(c)</akn:num><akn:heading>Major manufacturing changes</akn:heading><akn:content><akn:p>(c) Major manufacturing changes</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356a_d"><akn:num>(d)</akn:num><akn:heading>Other manufacturing changes</akn:heading><akn:content><akn:p>(d) Other manufacturing changes</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>